NASDAQ:SNGX
Soligenix, Inc Stock News
$0.405
+0 (+0%)
At Close: May 03, 2024
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
09:58am, Thursday, 09'th Sep 2021
The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
07:30am, Thursday, 09'th Sep 2021
PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review
08:30am, Tuesday, 24'th Aug 2021
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen cond
PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates
11:41am, Wednesday, 18'th Aug 2021
Soligenix Inc (NASDAQ: SNGX) announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform presentation. Data
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
08:52am, Wednesday, 18'th Aug 2021
PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
07:30am, Friday, 13'th Aug 2021
PRINCETON, N.J., Aug. 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma
08:30am, Thursday, 22'nd Jul 2021
Soligenix Demonstrates Clinical Success in First-in-Class Treatment for Cutaneous T-Cell LymphomaNew York, New York--(Newsfile Corp. - July 22, 2021) - PCG Digital -- Cutaneous T-cell lymphoma (CTCL)
7 Reddit Penny Stocks to Bet On if You Have $100 to Gamble
02:12pm, Monday, 12'th Jul 2021
Reddit traders aren't just focused on short squeezes. Here are seven ultra-risky Reddit penny stocks that have caught their attention.
Offering New Hope for a Rare Form of non-Hodgkin's Lymphoma: A Discussion with Dr. Ellen Kim on HyBryte(TM) from Soligenix
08:30am, Tuesday, 06'th Jul 2021
New York, New York--(Newsfile Corp. - July 6, 2021) - PCG Digital -- A rare form of non-Hodgkin's lymphoma, cutaneous T-cell lymphoma (CTCL) has no current FDA-approved first-line therapies. There are
PRINCETON, N.J., June 22, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
SNGX Stock Price: Over 15% Increase Pre-Market Explanation
08:42am, Thursday, 10'th Jun 2021
The stock price of Soligenix, Inc. (NASDAQ: SNGX) increased by over 15% pre-market. This is why it happened.
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
07:30am, Thursday, 10'th Jun 2021
PRINCETON, N.J., June 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
07:30am, Wednesday, 09'th Jun 2021
PRINCETON, N.J., June 9, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
07:30am, Thursday, 20'th May 2021
PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
